A solicitor and former client is suing Corrs Chambers Westgarth for “very significant damages”, alleging breaches of multiple duties by the law firm in the course of protracted litigation.
Explaining his decision to reject a class action settlement that would have earned a law firm $1.75 million but provided nothing to 27,000 Woolworths employees, a judge has said the agreement created a conflict of interest between the solicitors and the workers they sought to set “adrift”.
One Nation chief-of-staff James Ashby has failed to revive his lawsuit alleging the federal government breached the Fair Work Act by not paying his $4.5 million legal bill stemming from a dropped sexual harassment case against former House speaker Peter Slipper.
Herbert Smith Freehills has partnered with the University of New South Wales on a practical training course for the firm’s Australian graduates that will allow them to start practicing sooner.
The NSW Court of Appeal has granted Bianca Rinehart’s bid for her billionaire mother Gina to hand over trust documents that could be used in a dispute over ownership of the $4 billion family trust.
Bill Papas’ girlfriend Louise Agostino has hit back at Westpac’s lawsuit accusing her of involvement in the Forum Group director’s alleged $294 million fraud, denying all allegations and arguing that the bulk of the bank’s claims against her should be struck out.
Big Six firm Herbert Smith Freehills has appointed a PricewaterhouseCoopers veteran as its first director of global workforce strategy and implementation.
Moray & Agnew is facing a lawsuit by a former client who says the firm breached its duties by making an unauthorised $3.3 million transfer while representing him on an investment in a Melbourne storage facility development.
AMP has admitted two of its units charged customers fees for no service but denied it acted unconscionably in a case brought by the corporate regulator alleging it continued to charge advice fees and life insurance premiums to customers who had died.
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.